Abstract #0018
GluCEST imaging in a primate model of Alzheimers disease
Julien Flament 1,2 , Charlotte Gary 2,3 , James Koch 2,4 , Fabien Pifferi 5 , Emmanuel Comoy 6 , Jean-Luc Picq 7 , Julien Valette 2,3 , and Marc Dhenain 2,3
1
INSERM US27, CRC-MIRCen, Fontenay-aux-Roses,
France,
2
CEA/DSV/I2BM/MIRCen,
Fontenay-aux-Roses, France,
3
CNRS
URA 2210, Fontenay-aux-Roses, France,
4
Department
of Psychology, University of Wisconsin, Oshkosh, WI,
United States,
5
CNRS-MNHN
UMR 7179, Brunoy, France,
6
CEA/DSV/iMETI/SEPIA,
Fontenay-aux-Roses, France,
7
EA
2027, Universit Paris 8, Saint-Denis, France
This study describes the possibility to image glutamate
concentration alterations using gluCEST. Injection of
brain homogenates of Alzheimers disease (AD) patients
in susceptible mice can induce or accelerate the
pathology, suggesting a prion-like mechanism. Here,
two groups of mouse lemur primates were injected with
brain homogenate of either AD (n=4) or age-matched
control patients (n=3). They were characterized by MRS,
showing modifications in metabolic profile, especially a
decrease in glutamate concentration (-16.5%). GluCEST
images showed a decrease of gluCEST contrast (-17.6%)
reflecting glutamate concentration variation. These
results suggest that glutamate level could be a
surrogate marker of disease progression.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
